Free Trial

Short Interest in Enhabit, Inc. (NYSE:EHAB) Rises By 48.7%

Enhabit logo with Medical background

Enhabit, Inc. (NYSE:EHAB - Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 1,680,000 shares, an increase of 48.7% from the September 30th total of 1,130,000 shares. Currently, 3.8% of the company's shares are short sold. Based on an average daily trading volume, of 664,300 shares, the short-interest ratio is currently 2.5 days.

Enhabit Stock Down 2.0 %

Shares of NYSE:EHAB traded down $0.14 during midday trading on Tuesday, hitting $6.99. 232,489 shares of the company's stock were exchanged, compared to its average volume of 589,724. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.48 and a quick ratio of 1.48. The stock has a 50 day moving average price of $7.74 and a 200-day moving average price of $8.73. The company has a market cap of $351.46 million, a PE ratio of -41.12 and a beta of 1.81. Enhabit has a 12 month low of $6.89 and a 12 month high of $11.74.

Enhabit (NYSE:EHAB - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.05 by $0.02. The firm had revenue of $260.60 million for the quarter, compared to analysts' expectations of $265.99 million. Enhabit had a negative net margin of 0.84% and a positive return on equity of 1.61%. During the same quarter last year, the firm earned $0.04 EPS. On average, sell-side analysts anticipate that Enhabit will post 0.26 EPS for the current fiscal year.

Insider Activity at Enhabit

In related news, Director Jeffrey Bolton purchased 5,000 shares of the firm's stock in a transaction on Thursday, August 22nd. The stock was purchased at an average cost of $8.01 per share, with a total value of $40,050.00. Following the completion of the purchase, the director now owns 78,877 shares in the company, valued at approximately $631,804.77. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Enhabit

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. AREX Capital Management LP raised its holdings in shares of Enhabit by 2.5% in the 2nd quarter. AREX Capital Management LP now owns 2,472,662 shares of the company's stock worth $22,056,000 after purchasing an additional 59,353 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Enhabit by 1.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,756,745 shares of the company's stock valued at $15,669,000 after buying an additional 26,753 shares during the last quarter. Paradice Investment Management LLC lifted its position in shares of Enhabit by 0.7% during the 2nd quarter. Paradice Investment Management LLC now owns 1,525,037 shares of the company's stock valued at $13,603,000 after buying an additional 11,128 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in shares of Enhabit by 52.3% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 518,412 shares of the company's stock worth $4,306,000 after acquiring an additional 178,000 shares during the period. Finally, Kent Lake Capital LLC bought a new position in shares of Enhabit during the 1st quarter worth $5,183,000.

About Enhabit

(Get Free Report)

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.

Read More

Should you invest $1,000 in Enhabit right now?

Before you consider Enhabit, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enhabit wasn't on the list.

While Enhabit currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines